CN Patent

CN100374462C — 截短胰高血糖素样肽1(sGLP-1)、制法及其应用

Assigned to DIEN BIOLOGICAL ENGINEERING Co Ltd DALIAN · Expires 2008-03-12 · 18y expired

What this patent protects

本发明涉及促胰岛素分泌的胰高血糖素样肽1(glucagon-likepeptide-1，GLP-1)的类似物，截短胰高血糖素样肽1(sGLP-1)，其由26个氨基酸组成，其序列如下：His-X1-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu。本发明所述的截短胰高血糖素样肽1(sGLP-1)与目前GLP-1及其类似物相比，具有突出的特点：1.截短肽链改构后与胰岛细胞受体结合力更强，刺激更强的胰岛素分泌作用；2.通…

USPTO Abstract

本发明涉及促胰岛素分泌的胰高血糖素样肽1(glucagon-likepeptide-1，GLP-1)的类似物，截短胰高血糖素样肽1(sGLP-1)，其由26个氨基酸组成，其序列如下：His-X1-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu。本发明所述的截短胰高血糖素样肽1(sGLP-1)与目前GLP-1及其类似物相比，具有突出的特点：1.截短肽链改构后与胰岛细胞受体结合力更强，刺激更强的胰岛素分泌作用；2.通过第二位氨基酸序列的改变，由Ala改为Gly或Ser使改构的模拟序列可抵抗二肽基肽酶降解作用，从而使半衰期延长，药效增强；3.通过截短肽链，降低合成成本。

Drugs covered by this patent

Patent Metadata

Patent number
CN100374462C
Jurisdiction
CN
Classification
—
Expires
2008-03-12
Drug substance claim
No
Drug product claim
No
Assignee
DIEN BIOLOGICAL ENGINEERING Co Ltd DALIAN
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.